Julia Alterman
Sitert av
Sitert av
Exosome-mediated delivery of hydrophobically modified siRNA for huntingtin mRNA silencing
MC Didiot, LM Hall, AH Coles, RA Haraszti, BMDC Godinho, K Chase, ...
Molecular Therapy 24 (10), 1836-1847, 2016
RNAi modulation of placental sFLT1 for the treatment of preeclampsia
AA Turanov, A Lo, MR Hassler, A Makris, A Ashar-Patel, JF Alterman, ...
Nature biotechnology 36 (12), 1164-1173, 2018
Hydrophobically modified siRNAs silence huntingtin mRNA in primary neurons and mouse brain
JF Alterman, LM Hall, AH Coles, MR Hassler, MC Didiot, K Chase, ...
Molecular Therapy-Nucleic Acids 4, 2015
Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo
MR Hassler, AA Turanov, JF Alterman, RA Haraszti, AH Coles, MF Osborn, ...
Nucleic acids research 46 (5), 2185-2196, 2018
A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system
JF Alterman, BMDC Godinho, MR Hassler, CM Ferguson, D Echeverria, ...
Nature biotechnology 37 (8), 884-894, 2019
5΄-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo
RA Haraszti, L Roux, AH Coles, AA Turanov, JF Alterman, D Echeverria, ...
Nucleic acids research 45 (13), 7581-7592, 2017
Visualization of self-delivering hydrophobically modified siRNA cellular internalization
S Ly, DM Navaroli, MC Didiot, J Cardia, L Pandarinathan, JF Alterman, ...
Nucleic acids research 45 (1), 15-25, 2017
Heavily and fully modified RNAs guide efficient SpyCas9-mediated genome editing
A Mir, JF Alterman, MR Hassler, AJ Debacker, E Hudgens, D Echeverria, ...
Nature Communications 9 (1), 2641, 2018
Optimized cholesterol-siRNA chemistry improves productive loading onto extracellular vesicles
RA Haraszti, R Miller, MC Didiot, A Biscans, JF Alterman, MR Hassler, ...
Molecular Therapy 26 (8), 1973-1982, 2018
Serum deprivation of mesenchymal stem cells improves exosome activity and alters lipid and protein composition
RA Haraszti, R Miller, ML Dubuke, HE Rockwell, AH Coles, E Sapp, ...
Iscience 16, 230-241, 2019
Fully stabilized asymmetric sirna
A Khvorova, N Aronin, M Hassler, J Alterman
US Patent App. 15/089,423, 2016
Oligonucleotide compounds for targeting huntingtin mRNA
A Khvorova, N Aronin, J Alterman
Guanabenz (Wytensin™) selectively enhances uptake and efficacy of hydrophobically modified siRNAs
MF Osborn, JF Alterman, M Nikan, H Cao, MC Didiot, MR Hassler, ...
Nucleic acids research 43 (18), 8664-8672, 2015
A High-Throughput Method for Direct Detection of Therapeutic Oligonucleotide-Induced Gene Silencing In Vivo
AH Coles, MF Osborn, JF Alterman, AA Turanov, BMDC Godinho, ...
nucleic acid therapeutics 26 (2), 86-92, 2016
Transvascular delivery of hydrophobically modified siRNAs: gene silencing in the rat brain upon disruption of the blood-brain barrier
BMDC Godinho, N Henninger, J Bouley, JF Alterman, RA Haraszti, ...
Molecular Therapy 26 (11), 2580-2591, 2018
Synthesis and biological properties of triazole-linked locked nucleic acid
VK Sharma, SK Singh, PM Krishnamurthy, JF Alterman, RA Haraszti, ...
Chemical Communications 53 (63), 8906-8909, 2017
Loss of huntingtin function slows synaptic vesicle endocytosis in striatal neurons from the httQ140/Q140 mouse model of Huntington's disease
RL McAdam, A Morton, SL Gordon, JF Alterman, A Khvorova, MA Cousin, ...
Neurobiology of disease 134, 104637, 2020
Fully stabilized asymmetric sirna
A Khvorova, N Aronin, M Hassler, J Alterman
US Patent App. 15/691,120, 2017
An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis
B Yenilmez, N Wetoska, M Kelly, D Echeverria, K Min, L Lifshitz, ...
Molecular Therapy 30 (3), 1329-1342, 2022
Branched oligonucleotides
A Khvorova, M Hassler, J Alterman, BM da Cruz Godinho
US Patent 10,478,503, 2019
Systemet kan ikke utføre handlingen. Prøv på nytt senere.
Artikler 1–20